<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endometrial hyperplasia: Management and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endometrial hyperplasia: Management and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endometrial hyperplasia: Management and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Renata R Urban, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan D Reed, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1483970130"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Endometrial hyperplasia (EH) is categorized into two groups: EH without atypia and EH with atypia (also referred to as endometrial intraepithelial neoplasia [EIN]). EH with atypia is neoplastic and may progress or coexist with endometrial carcinoma. Early diagnosis and treatment of EH (with or without atypia) can prevent progression to endometrial carcinoma.</p><p>Terminology of EH varies widely  (<a class="graphic graphic_table graphicRef115177" href="/d/graphic/115177.html" rel="external">table 1</a>). This topic will utilize the 2014 World Health Organization classification criteria [<a href="#rid1">1</a>]. However, supporting studies cited in this topic may use other classification systems, which will be documented where appropriate. In addition, as there is significant overlap of EH with atypia and EIN, recommendations made in this topic for patients with EH with atypia can be applied to patients with EIN.</p><p>Management of EH is reviewed here. Related topics can be found separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3217.html" rel="external">"Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14204.html" rel="external">"Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy"</a>.)</p><p></p><p class="headingAnchor" id="H3414720904"><span class="h1">GOAL OF MANAGEMENT</span><span class="headingEndMark"> — </span>When managing patients with EH, the goal is to identify coexisting, and prevent progression to, endometrial carcinoma.</p><p>Management is guided by the following clinical factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Type of EH (ie, with or without atypia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Menopausal status</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Desire for fertility in premenopausal patients</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contraceptive needs in premenopausal patients</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for disease recurrence or progression, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age &gt;50 years [<a href="#rid2">2</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Body mass index (BMI) &gt;25 kg/m<sup>2</sup> [<a href="#rid2">2</a>] </p><p class="bulletIndent2"><span class="glyph">•</span>Nulliparity [<a href="#rid3">3</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Diabetes mellitus [<a href="#rid2">2</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>EH with atypia [<a href="#rid2">2</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Uterine size ≥9 cm [<a href="#rid4">4</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Endometrial lesion size &gt;2 cm [<a href="#rid5">5</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Lack of adequate progestin therapy [<a href="#rid3">3</a>]</p><p></p><p class="bulletIndent1">These risk factors are similar to those for the development of EH and endometrial carcinoma  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 2</a>). However, one confounder is the inability to distinguish progression of EH from a missed concurrent endometrial carcinoma. In addition, these risk factors vary in degree of risk, and the clinician must decide with the patient whether a particular factor is clinically significant and how it impacts management decisions. (See  <a class="medical medical_review" href="/d/html/3217.html" rel="external">"Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis", section on 'Risk factors'</a>.)</p><p></p><p class="headingAnchor" id="H1979260317"><span class="h1">EH WITHOUT ATYPIA</span></p><p class="headingAnchor" id="H1870025805"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>The risk of progression of EH without atypia to endometrial carcinoma has not been well studied but appears to be less than 10 percent, based on studies with up to 20 years of follow-up [<a href="#rid6">6-10</a>]. Representative studies of EH without atypia in the absence of treatment are rare but include:</p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 35 patients (mean age 46 years) with simple hyperplasia (ie, EH without atypia) managed expectantly for six months, approximately 74 percent of cases spontaneously regressed, 17 percent persisted, and 9 percent progressed to atypical hyperplasia; endometrial carcinoma was diagnosed in one patient (2.9 percent) [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an often-cited case series including 122 patients with simple and complex hyperplasia without atypia (ie, EH without atypia), the majority (approximately 90 percent) of whom were not treated with progestin therapy, two patients (1.6 percent) developed endometrial carcinoma after a mean duration of 10 years [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A higher progression rate to endometrial carcinoma (five-year cumulative rate of approximately 10 percent) was noted in a cohort study including 164 patients with complex hyperplasia (ie, EH without atypia) who did not receive progestin therapy [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H3764476810"><span class="h2">Preferred: Medical or surgical treatment</span><span class="headingEndMark"> — </span>We recommend medical or surgical treatment rather than observation for most patients with a diagnosis of EH without atypia. The choice of treatment depends on menopausal status, desire for fertility, contraceptive needs, and patient-specific risk factors for progression  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premenopausal</strong> patients not meeting the criteria for low risk of progression detailed below (see <a class="local">'Alternate for patients at low risk of progression: Observation'</a> below) are treated with progestin therapy  (<a class="graphic graphic_algorithm graphicRef131599" href="/d/graphic/131599.html" rel="external">algorithm 1</a>). Progestin therapy includes intrauterine and oral progestins and combined estrogen and progestin oral contraceptives (COCs). Our approach to prescribing these therapies is described in detail below. (See <a class="local">'Progestin therapy'</a> below.)</p><p></p><p class="bulletIndent1">Premenopausal patients with the inability to tolerate, or more rarely with contraindications to, progestins may undergo observation rather than treatment and are followed closely, as described below. (See <a class="local">'EH without atypia: Premenopausal patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postmenopausal</strong> patients are treated with either progestin therapy or hysterectomy  (<a class="graphic graphic_algorithm graphicRef131603" href="/d/graphic/131603.html" rel="external">algorithm 2</a>); the choice depends on the perceived risk of developing endometrial carcinoma based on their personal risk factors (eg, chronic ovulatory dysfunction, obesity, early menarche, late menopause, increasing age, <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> therapy, Lynch syndrome, Cowden syndrome  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 2</a>)). (See <a class="local">'Goal of management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most postmenopausal patients are appropriate candidates for progestin therapy, which may be intrauterine or oral; COCs are<strong> not</strong> used in postmenopausal patients to avoid unnecessary exposure to estrogen, which may result in further risk (eg, venous thromboembolism). Our approach to therapy is described in detail below. (See <a class="local">'Progestin therapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hysterectomy is curative for EH and is performed in postmenopausal patients in whom progestin therapy is declined or contraindicated, in those with bothersome bleeding, in those at highest risk of developing endometrial carcinoma, or in those who desire definitive therapy. (See <a class="local">'Hysterectomy'</a> below.)</p><p></p><p class="headingAnchor" id="H2982881365"><span class="h2">Alternate for patients at low risk of progression: Observation</span><span class="headingEndMark"> — </span>We recommend observation rather than treatment for patients with a diagnosis of EH without atypia in whom the risk of progression to endometrial carcinoma is low. These patients are premenopausal and have one or more of the following  (<a class="graphic graphic_algorithm graphicRef131599" href="/d/graphic/131599.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>The inciting factor that resulted in endometrial proliferation has been eliminated (eg, patient with anovulation, now corrected).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other risk factors for endometrial carcinoma are <strong>not</strong> present  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resumption of normal menses; ovulation and formation of a corpus luteum exposes the endometrium to high endogenous <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> levels that are often sufficient to cause regression of EH without atypia.</p><p></p><p>Our approach to following these patients is discussed below. (See <a class="local">'EH without atypia: Premenopausal patients'</a> below.)</p><p class="headingAnchor" id="H3783742847"><span class="h2">Evidence of the efficacy of progestin therapy</span><span class="headingEndMark"> — </span>Data suggest that progestin therapy is an effective treatment for EH without atypia [<a href="#rid9">9-17</a>]; representative studies are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In a nested case control study from a managed care organization including 63 patients with a diagnosis of EH without atypia of whom the majority (over 80 percent) received medical therapy and developed endometrial carcinoma, cumulative rates of progression to endometrial carcinoma were 1.2, 1.9, and 4.6 percent at 4, 9, and 19 years, respectively [<a href="#rid9">9,10</a>]. In the cohort study described above (see <a class="local">'Natural history'</a> above), of the 1037 patients with a diagnosis of EH without atypia treated with progestin therapy, the rate of progression to endometrial carcinoma was approximately 2 percent at 10 years [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 24 observational studies including over 1000 patients with simple and complex hyperplasia (ie, EH without atypia), regression rates with oral progestin therapy were between 66 and 89 percent, with the degree of glandular crowding being inversely related to regression rate [<a href="#rid11">11</a>]. Regression rates were even higher with the <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG)-releasing intrauterine device (IUD [LNG 52 mg; 92 to 96 percent; total of 174 patients]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent meta-analysis of seven randomized trials also demonstrated that the LNG 52 mg was more effective than oral progestins for the treatment of EH without atypia; the LNG 52 mg had a higher response rate at six months in four trials (88 versus 69 percent, odds ratio [OR] 3.16, 95% CI 1.84-5.45) and a lower hysterectomy rate (OR 0.26, 95% CI 0.15-0.45) [<a href="#rid13">13</a>]. (See <a class="local">'Progestin therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relapse rates may also be lower after treatment with LNG 52 mg compared with oral progestins. One cohort study including over 200 patients with complex EH (ie, EH without atypia) and long-term follow-up (&gt;5 years) after treatment with either the LNG 52 mg or oral progestin therapy showed a relapse rate of approximately 13 and 28 percent, respectively [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H1192337015"><span class="h1">EH WITH ATYPIA (EIN)</span></p><p class="headingAnchor" id="H3031444329"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>The risk of progression of EH with atypia (endometrial intraepithelial neoplasia [EIN]) to endometrial carcinoma is<strong> </strong>higher than that of EH without atypia and is between 15 and 40 percent, based on studies with up to 20 years of follow-up [<a href="#rid7">7-9,18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a case series including 48 patients with EH with atypia, 83 percent of whom were not treated with progestin therapy, eleven patients (23 percent) developed endometrial carcinoma after a mean duration of approximately five years [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A higher progression rate to endometrial carcinoma (five-year cumulative rate of approximately 40 percent) was noted in a cohort study including 62 patients with EH with atypia who did not receive treatment [<a href="#rid8">8</a>].</p><p></p><p>Coexistent endometrial carcinoma may be present in up to 40 percent of patients with EH with atypia [<a href="#rid19">19,20</a>]; risk factors for concomitant endometrial carcinoma include increased age, obesity, diabetes mellitus, and postmenopausal patients with a transvaginal ultrasound showing an endometrial thickness ≥20 mm [<a href="#rid21">21-23</a>]. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3217.html" rel="external">"Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis", section on 'Natural history'</a>.)</p><p class="headingAnchor" id="H2546403009"><span class="h2">Preferred treatment: Hysterectomy</span><span class="headingEndMark"> — </span>Given the high risk of concurrent, or progression to, endometrial carcinoma, for most postmenopausal patients and premenopausal patients who have completed childbearing, we recommend definitive treatment with hysterectomy for treatment of EH with atypia  (<a class="graphic graphic_algorithm graphicRef131604" href="/d/graphic/131604.html" rel="external">algorithm 3</a> and <a class="graphic graphic_algorithm graphicRef131597" href="/d/graphic/131597.html" rel="external">algorithm 4</a>). In a longitudinal study of patients with hyperplasia (with and without atypia), the only EH-related deaths were in patients with endometrial carcinoma at the time of surgery [<a href="#rid8">8</a>]. (See <a class="local">'Hysterectomy'</a> below.)</p><p>It is also important to address any underlying conditions that may have led to the development of EH. For example, patients with obesity may benefit from referral for medical and/or surgical weight loss [<a href="#rid24">24</a>].</p><p>Patients that are at high risk for surgical complications may be managed with progestin therapy rather than surgery, as discussed below. (See <a class="local">'Alternate treatment: Progestin therapy'</a> below.)</p><p class="headingAnchor" id="H3346277092"><span class="h2">Alternate treatment: Progestin therapy</span><span class="headingEndMark"> — </span>Historically, the recommendation for treatment of EH with atypia was with hysterectomy, and few exceptions were made. However, with increasing data regarding efficacy of pharmacologic therapy, and after the introduction of the <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG)-releasing intrauterine device (IUD [LNG 52 mg]), progestins became an alternative treatment for some patients, though long-term surveillance and medical therapy are required and treatment may not be curative, as with hysterectomy [<a href="#rid11">11,14-17,25-35</a>]. We consider progestin therapy a reasonable alternative to hysterectomy for the following  (<a class="graphic graphic_algorithm graphicRef131604" href="/d/graphic/131604.html" rel="external">algorithm 3</a> and <a class="graphic graphic_algorithm graphicRef131597" href="/d/graphic/131597.html" rel="external">algorithm 4</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Premenopausal patients who desire future fertility</p><p class="bulletIndent1"><span class="glyph">●</span>Patients of any reproductive status who decline hysterectomy</p><p class="bulletIndent1"><span class="glyph">●</span>Patients at high risk of surgical complications</p><p></p><p>These patients must be able to comply with medical therapy and follow-up endometrial sampling.</p><p>Progestin therapy includes intrauterine and oral progestins. Combined estrogen and progestin oral contraceptives (COCs) are not used for the treatment of EH with atypia. Our approach to prescribing these therapies is described in detail below. (See <a class="local">'Progestin therapy'</a> below.)</p><p class="headingAnchor" id="H1291163264"><span class="h2">Evidence of the efficacy of progestin therapy</span><span class="headingEndMark"> — </span>The efficacy of progestins for treatment of EH with atypia is supported by the following evidence:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort study including over 240 patients who had EH with atypia, patients treated with progestin (180 patients) compared with untreated patients (62 patients) had lower rates of endometrial carcinoma (20.5 versus 101.4 per 1000 person-years) and hysterectomy (61 versus 297 per 1000 person-years) [<a href="#rid8">8</a>]. However, disease persistence and recurrence remain high after treatment. In this study, of the 180 patients with EH with atypia treated with progestin therapy, 27 patients (15 percent) developed endometrial carcinoma by 10 years [<a href="#rid8">8</a>]. Similarly, in one systematic review including 111 patients with EH with atypia treated with progestin therapy (median age 31.7 years), persistent disease and disease recurrence were noted in 14 and 23 percent of patients, respectively [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the nested case control study from a managed care organization of patients with EH described above (see <a class="local">'Evidence of the efficacy of progestin therapy'</a> above), among those who had EH with atypia and developed endometrial carcinoma (42 patients; 86 to 92 percent of whom received progestin treatment), rates of progression to endometrial carcinoma were 8.2, 12.4, and 27.5 percent at 4, 9, and 19 years, respectively [<a href="#rid9">9,10</a>]. Subjects were diagnosed with carcinoma an average of six years after initial diagnosis (range 1 to 24 years).</p><p></p><p>While various oral progestin therapies are effective for this indication (see <a class="local">'Oral progestins'</a> below), the LNG 52 mg IUD (Mirena, Liletta) is the most effective first-line therapy [<a href="#rid11">11,17,26-30</a>]. Studies of patients who have EH with atypia have consistently demonstrated that the LNG 52 mg compared with oral progestins is associated with higher regression rates (90 versus 69 percent [<a href="#rid11">11</a>]), lower relapse rates (27 versus 50 percent [<a href="#rid17">17</a>]), and fewer subsequent hysterectomies (23 versus 36 percent [<a href="#rid36">36</a>]). In addition, patients with a higher body mass index (BMI) may derive a greater relative benefit from the LNG 52 mg than those with lower BMIs [<a href="#rid30">30</a>]; however, further study is needed to support this finding.</p><p class="headingAnchor" id="H3733943060"><span class="h1">TREATMENT ADMINISTRATION</span></p><p class="headingAnchor" id="H3556573774"><span class="h2">Progestin therapy</span></p><p class="headingAnchor" id="H2824839636"><span class="h3">General considerations</span><span class="headingEndMark"> — </span>Various progestin preparations have been used for treatment of EH  (<a class="graphic graphic_table graphicRef115020" href="/d/graphic/115020.html" rel="external">table 3</a>), although none have received US Food and Drug Administration-approval for this indication. However, some have received approval for prevention of EH, and <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> and depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA) are approved for treatment of endometrial carcinoma.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – Progestins reverse EH by activation of <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> receptors, which results in stromal decidualization and subsequent thinning of the endometrium. Progestin exposure also activates hydroxylase enzymes to convert estradiol to its less active metabolite <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – Some data suggest that high-dose oral progestins (ie, <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a>, <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> acetate) and DMPA increase the risk of venous thromboembolism (VTE) [<a href="#rid38">38</a>]. Other progestins (eg, oral norethindrone, micronized <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a>) appear to pose minimal or no increased VTE risk; <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> was not included in this study. Thus, consultation with a hematologist may be appropriate for patients in whom high-dose oral progestins or DMPA are being recommended. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'Other progestin-only therapies'</a> and  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Cardiovascular and thromboembolic risk'</a>.)</p><p></p><p class="bulletIndent1">Contraindications to the <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG)-releasing intrauterine device (IUD [LNG 52 mg; Mirena, Liletta]; also referred to as an intrauterine system) are discussed in detail elsewhere. It is important to note that the LNG 52 mg administers progestins locally to the uterus and results in minimal systemic absorption; these devices are not associated with an increased risk of VTE [<a href="#rid38">38</a>]. Thus, the LNG 52 mg is often preferred over high-dose oral progestins and <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>. (See  <a class="medical medical_review" href="/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection", section on 'Contraindications'</a> and  <a class="medical medical_review" href="/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'How to choose'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuous versus cyclic regimens</strong> – In terms of dosing, continuous progestins (daily dosing oral progestins or progestin IUDs) are superior in efficacy compared with cyclic progestin regimens (dosing varies; medication is typically taken for at least 12 to 14 days and then the patient receives no medication for the remainder of the month) [<a href="#rid27">27,39</a>]. Thus, a continuous dosing regimen is preferred over a cyclic regimen if amenorrhea can be achieved. Cyclic regimens may be used in patients who cannot tolerate, or do not want to use, a continuous regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – Some patients experience bothersome progestin side effects (eg, irregular vaginal bleeding, bloating, irritability, depression, headaches) and may require an adjustment in dose or a switch to a different progestin formulation. Side effects are more likely with oral progestins, and in these situations, we advise changing to the LNG 52 mg, which has a more favorable side effect profile.</p><p></p><p class="headingAnchor" id="H1870411841"><span class="h3">Choice of progestin</span><span class="headingEndMark"> — </span>The LNG 52 mg (Mirena, Liletta) is our choice for first-line progestin therapy in patients with EH (with and without atypia) [<a href="#rid11">11-13,16,17,26-30,34,35,40-42</a>], although historically, the most common treatments were oral <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (MPA) or <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a>. Studies have consistently demonstrated that the LNG 52 mg compared with oral progestins for the treatment of EH is associated with higher regression rates and lower relapse rates for the treatment of EH with (see <a class="local">'Evidence of the efficacy of progestin therapy'</a> above) and without (see <a class="local">'Evidence of the efficacy of progestin therapy'</a> above) atypia. In addition to higher efficacy, these devices may be used in patients with relative contraindications to progestins, offer long-acting contraception, and do not require daily dosing [<a href="#rid16">16,18,34</a>]. They are also typically better tolerated than oral progestins, although the meta-analysis of randomized trials discussed above found no significant difference in rates of irregular vaginal bleeding with the LNG 52 mg compared with oral progestins [<a href="#rid13">13</a>].</p><p>Oral progestins are an acceptable alternative for patients who decline, cannot tolerate (eg, difficult insertion, repetitive expulsions), or are not candidates for an <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUD</a>. (See  <a class="medical medical_review" href="/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection", section on 'Contraindications'</a>.)</p><p>When oral agents are used for treatment of EH with atypia, <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> is preferred because it is more potent than other progestins, such as MPA [<a href="#rid32">32,33</a>]  (<a class="graphic graphic_table graphicRef115020" href="/d/graphic/115020.html" rel="external">table 3</a>). Other oral progestin treatment options are similar to those for EH without atypia, although oral norethisterone and micronized <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> have not been adequately studied in patients who have EH with atypia. Often, higher progestin doses are used for EH with atypia compared with doses recommended for EH without atypia, although there are minimal data to support this approach. (See <a class="local">'Oral progestins'</a> below.)</p><p class="headingAnchor" id="H422460111"><span class="h3">Levonorgestrel-releasing IUD (LNG 52 mg)</span><span class="headingEndMark"> — </span>The initial LNG 52 mg dose is 20 mcg/day; by five years the daily dose is approximately 10 mcg/day. While the LNG 52 mg is approved for six (Liletta) or seven (Mirena) years of use as a contraceptive, we remove and replace the IUD at five years when treating EH. Lower dose LNG-releasing IUDs are also available (13.5, 17.5, and 18.6 mcg/day) and vary from three- to five-year formulations, but these have not been studied in patients with EH to determine whether the lower progestin dose is as effective as the LNG 52 mg. We do not use them for this indication in our practice. Detailed general information about use of the <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUD</a> can be found separately.(See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'</a> and  <a class="medical medical_review" href="/d/html/3267.html" rel="external">"Intrauterine contraception: Insertion and removal"</a> and  <a class="medical medical_review" href="/d/html/5422.html" rel="external">"Intrauterine contraception: Management of side effects and complications"</a>.)</p><p class="headingAnchor" id="H1493673234"><span class="h3">Oral progestins</span><span class="headingEndMark"> — </span>Oral progestins may be given as progestins alone (eg, <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a>, MPA); in premenopausal patients without atypia, combined estrogen and progestin oral contraceptives (COCs) may also be used [<a href="#rid43">43</a>]. Patients are usually treated for three to six months with continuous dosing [<a href="#rid44">44</a>]. Studies comparing higher-dose progestins with the doses listed below have found no significant difference [<a href="#rid14">14,45</a>].</p><p>For patients with EH (with or without atypia) who are treated with <strong>noncontraceptive</strong> oral progestins, medications, doses, and regimens that have been reported are, in order of our preference:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">Megestrol acetate</a> 40 to 160 mg daily [<a href="#rid32">32,46</a>]; however, no standard dose is routinely prescribed and higher doses have been reported [<a href="#rid11">11</a>]. One contributor's (BG) practice is to use 40 mg twice daily for patients with EH without atypia and 80 mg twice daily for patients with EH with atypia. This medication is considered a "chemotherapeutic agent," but it is best classified as a strong progestin [<a href="#rid15">15</a>]. As megestrol acetate is an appetite stimulant and associated with weight gain, particularly at higher doses, we dose based on shared decision making and tolerance of side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">Medroxyprogesterone acetate</a><strong> </strong>(MPA) 10 to 20 mg daily [<a href="#rid27">27,47</a>]; however, no standard dose is routinely prescribed and higher doses have been reported [<a href="#rid11">11,26,45</a>]. MPA was one of the first-line therapies for EH before the LNG 52 mg was studied for this indication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">Norethindrone</a><strong> acetate</strong> (NETA, also known as norethisterone acetate; eg, Aygestin) 5 to 15 mg daily; however, this has not been well studied. Studies with small numbers of patients taking NETA suggest similar efficacy to oral MPA [<a href="#rid14">14,48,49</a>] but lower efficacy than <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> [<a href="#rid50">50</a>]. (See <a class="local">'Depot medroxyprogesterone acetate'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Micronized </strong><a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> 200 to 300 mg daily was beneficial in a single study of patients with EH [<a href="#rid51">51</a>]. However, this is a relatively weak progestin, and we do not consider it for first-line progestin treatment. In our practice, we use it only for EH without atypia (because these patients are at low risk for progression to endometrial carcinoma) and in those who cannot tolerate stronger synthetic progestins or refuse the LNG 52 mg.</p><p></p><p>For patients who require <strong>contraception</strong>, medications, doses, and regimens that have been reported are:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">Norethindrone</a><strong> </strong>(progestin-only contraceptive pill; eg, Micronor) 0.35 mg twice or three times daily; however, this has not been well studied. In addition, norethindrone, when given daily, has lower contraceptive efficacy than the LNG 52 mg or COCs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined estrogen and progestin contraceptives</strong> (COCs); although COCs (available in pills, patches, and rings) have not been studied for treatment of EH<strong> </strong>progestin, the dose of progestin is, in theory, sufficient to reverse the majority of cases of EH without atypia [<a href="#rid52">52,53</a>]. In addition, COCs are associated with a lower risk of developing endometrial cancer [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Use of hormonal contraception'</a>.)</p><p></p><p class="headingAnchor" id="H281089858"><span class="h3">Depot medroxyprogesterone acetate</span><span class="headingEndMark"> — </span>Progestin injections have not been well studied for the treatment of EH [<a href="#rid50">50,55</a>]. One of the authors uses <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>, a long-acting progestin contraceptive requiring only four injections per year, as subsequent-line therapy for premenopausal patients with EH without atypia who are intolerant of oral progestins or the LNG 52 mg.</p><p>One study found that the intramuscular <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> (150 mg every three months) was more successful than NETA (15 mg daily for 14 days per cycle) in the treatment of EH without atypia [<a href="#rid50">50</a>]. In this six-month randomized trial including 146 patients ages 35 to 50 years with EH without atypia, rates of regression to normal endometrium were higher with DMPA compared with NETA (91 versus 67 percent, relative risk [RR] 1.4, 95% CI 1.2-1.6). Side effects were present with both medications, with more nausea and breast discomfort with NETA and more amenorrhea with DMPA.</p><p class="headingAnchor" id="H1379974149"><span class="h3">Other preparations</span><span class="headingEndMark"> — </span>Progestin implants (ie, etonogestrel; Nexplanon) and vaginal micronized <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> [<a href="#rid56">56,57</a>] have not been well studied for the treatment of EH, and we do not typically use these in our practice.</p><p>A small study of infertility patients found that vaginal micronized <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> had similar effects on the endometrium as intramuscular progesterone, with no EH seen [<a href="#rid57">57</a>]. In theory, this progestin could be used as maintenance treatment, as its local effect achieves high endometrial concentrations.</p><p class="headingAnchor" id="H3022341792"><span class="h2">Hysterectomy</span><span class="headingEndMark"> — </span>Total extrafascial hysterectomy is the definitive treatment for EH. Supracervical hysterectomy is not performed, in part because of the potential for local extension of endometrial neoplasia into the cervix [<a href="#rid25">25</a>].</p><p>All measures should be taken to detect endometrial carcinoma before or during hysterectomy. Because of variations in interpretation of EH, if hysterectomy is planned based on a single endometrial specimen, we have the slides reviewed by a second pathologist to confirm the classification [<a href="#rid58">58</a>]. In addition, if the diagnosis of EH with atypia is based on an office endometrial biopsy, we advise further evaluation with D&amp;C (with or without hysteroscopy) prior to proceeding with hysterectomy to exclude coexistent endometrial carcinoma [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/3217.html" rel="external">"Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis", section on 'Subsequent evaluation of EH with atypia'</a> and  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease", section on 'Postmenopausal patients with bleeding'</a>.)</p><p>During hysterectomy, gross inspection, and frozen section when appropriate, are typically performed to evaluate for endometrial carcinoma. Reports of the sensitivity of frozen section to detect endometrial carcinoma mostly range from 73 to 88 percent [<a href="#rid60">60-62</a>], although one study reported a sensitivity of 27 percent [<a href="#rid63">63</a>]. Thus, some patients will have endometrial carcinoma detected only on final pathology evaluation.</p><p>Patients with endometrial carcinoma detected at surgery should undergo full staging and be treated as appropriate. (See  <a class="medical medical_review" href="/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a>.)</p><p>Lymph node assessment at the time of hysterectomy for EH may be performed [<a href="#rid64">64</a>], and sentinel lymph node mapping for such patients has been described [<a href="#rid65">65</a>]. The discussion of when to perform such procedures can be done in consultation with a gynecologic oncologist.</p><p class="headingAnchor" id="H3195869919"><span class="h3">Role of oophorectomy and salpingectomy</span><span class="headingEndMark"> — </span>For most patients undergoing hysterectomy, we suggest hysterectomy with bilateral salpingectomy with or without bilateral oophorectomy; professional societies have not issued guidelines regarding removal or retention of ovaries in patients with EH. Patients with a hereditary ovarian cancer syndrome (eg, Lynch syndrome, Cowden syndrome) may be managed differently. (See  <a class="medical medical_review" href="/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer"</a>.)</p><p>Salpingectomy alone provides possible prevention of ovarian, fallopian tube, and peritoneal carcinomas. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction"</a>.)</p><p>The choice of oophorectomy depends on immediate and long-term negative health effects (eg, increased risk of cardiovascular disease, cognitive decline) and possible benefits (eg, avoiding the need for a subsequent oophorectomy, breast cancer risk reduction) of surgical menopause. (See  <a class="medical medical_review" href="/d/html/14198.html" rel="external">"Elective oophorectomy or ovarian conservation at the time of hysterectomy", section on 'Consequences of elective oophorectomy'</a>.)</p><p>Even in cases of endometrial carcinoma, the ovaries have metastatic disease in only 5 percent of cases [<a href="#rid66">66,67</a>]. In addition, patients with concurrent endometrial carcinoma are likely to have low-risk disease, and the likelihood of an impact on survival with retaining the ovaries in a patient with stage I, grade 1 endometrial carcinoma is low [<a href="#rid68">68,69</a>]. However, some experts still perform bilateral salpingo-oophorectomy (BSO) in all cases of EH with atypia because of the high risk of concomitant endometrial carcinoma and because BSO is a standard part of staging  (<a class="graphic graphic_table graphicRef141918" href="/d/graphic/141918.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef141963" href="/d/graphic/141963.html" rel="external">table 5</a>) [<a href="#rid19">19,70</a>].</p><p>For patients who do undergo oophorectomy, menopausal symptoms may be treated with postmenopausal estrogen therapy, if there are no contraindications. This is based on the safety of postmenopausal estrogen therapy in patients with early-stage endometrial carcinoma. (See  <a class="medical medical_review" href="/d/html/17006.html" rel="external">"Overview of approach to endometrial cancer survivors", section on 'Menopausal symptoms'</a>.)</p><p class="headingAnchor" id="H3678444207"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>Treatment with nonprogestin medications or uterine-sparing surgeries are not standard clinical practice, but have been described [<a href="#rid71">71,72</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonprogestin medications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gonadotropin-releasing hormone agonists were used in combination with an LNG 52 mg (Mirena, Liletta) to successfully treat 24 premenopausal patients with either EH with atypia or early-stage endometrial carcinoma [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ovulation induction (eg, with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> or aromatase inhibitors) in reproductive-age patients will result in formation of a corpus luteum, exposure to endogenous <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a>, and resolution of EH in some patients [<a href="#rid74">74</a>]. Administration of these therapies should be under the supervision of a reproductive endocrinology and infertility specialist along with consultation from gynecologic oncology. Pregnancy is highly unlikely in the setting of ongoing EH. Careful surveillance is needed to assure EH regression. This approach is favored for patients with EH without atypia who desire pregnancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> has been shown to have both antiproliferative effects and to reduce insulin resistance, which may play a role in the development of endometrial carcinoma in patients with obesity [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>.)</p><p></p><p class="bulletIndent2">In a meta-analysis of observational studies and randomized trials including a subset of 472 patients with EH with atypia, those treated with progestin plus <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> compared with progestin alone had lower rates of disease relapse (pooled odds ratio 0.46, 95% CI 0.24-0.91; three studies) but similar rates of disease remission (six studies) [<a href="#rid76">76</a>]. One limitation of this analysis is that patients with endometrial carcinoma were also included and outcomes were not distinguished between groups. Further research, including larger randomized trials, are needed before metformin can be recommended for routine use as an adjunct therapy with progestin in these patients [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other surgical treatments</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hysteroscopic resection of EH was reported to be effective in 68 of 73 treated patients, but the long-term consequence of this treatment remains to be determined [<a href="#rid78">78</a>]. A review of 36 patients treated with hysteroscopic tumor resection combined with hormone therapy reported an 89 percent response rate, with an 11 percent recurrence rate [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bariatric surgery may show promise [<a href="#rid80">80,81</a>]. In a retrospective study including over 1400 female patients with obesity, patients who underwent bariatric surgery had lower rates of cancer compared with patients who did not undergo bariatric surgery (3.5 versus 5.8 percent) [<a href="#rid82">82</a>]. The most frequent cancer in the group who had bariatric surgery was breast (28.3 percent), followed by endometrial (17 percent). In the control group, the most common cancer was endometrial (62.3 percent).</p><p></p><p class="headingAnchor" id="H180558147"><span class="h1">FOLLOW-UP</span></p><p class="headingAnchor" id="H1888983841"><span class="h2">General considerations after hysterectomy</span><span class="headingEndMark"> — </span>Following total hysterectomy, if there is no endometrial carcinoma in the specimen, no further surveillance related to EH is necessary. Vaginal cytology is <strong>not</strong> required for most patients, regardless of whether there is EH or endometrial carcinoma in the surgical specimen. Vaginal cancer is rare. Cytology of the vaginal cuff should be performed only if there is an indication based on the patient's history (eg, cervical intraepithelial neoplasia, in utero exposure to diethylstilbestrol), and not based on the history of EH. (See  <a class="medical medical_review" href="/d/html/3205.html" rel="external">"Cervical cancer screening: The cytology and human papillomavirus report", section on 'Vaginal cytology'</a>.)</p><p class="headingAnchor" id="H1166755314"><span class="h2">General considerations for patients managed with observation or progestins</span><span class="headingEndMark"> — </span>For patients with EH (with or without atypia) managed with observation or progestin therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>Careful follow-up is needed to assess for disease persistence, progression, or recurrence. If endometrial carcinoma is found at any time, the patient should be managed as appropriate. (See  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with exposure to unopposed estrogen, the source should be corrected (if possible), if not already done. Examples include encouraging weight loss, discontinuing unopposed estrogen therapy (including nonprescription medications or topical products) or adding a progestin, correcting ovulatory dysfunction, or, rarely, removing an estrogen-producing neoplasm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Median time for regression to normal endometrium on progestin therapy appears to be three (EH without atypia) to nine (EH with atypia) months [<a href="#rid14">14,31-33</a>]; hormone receptor status does not appear to affect the response or relapse rates [<a href="#rid83">83-85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mainstay of follow-up is repeat endometrial sampling, although some postmenopausal patients may be followed with transvaginal ultrasound once endometrial sampling has normalized (see <a class="local">'EH with atypia: Postmenopausal patients'</a> below). Some experts advise discontinuing oral progestins and waiting for a withdrawal bleed before endometrial sampling is performed, while others sample the endometrium while the patient is on oral progestin therapy [<a href="#rid25">25</a>]; the decidual reaction that occurs with progestin therapy may make it more difficult to interpret pathologic findings. In our practice, we do not discontinue oral progestin therapy prior to sampling.</p><p></p><p class="bulletIndent1">In patients with an intrauterine device (IUD), an endometrial biopsy may be performed with the device in place.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrence of EH is usually symptomatic (ie, abnormal uterine bleeding) and requires endometrial sampling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients may have persistent or recurrent abnormal uterine bleeding, despite no disease progression on serial endometrial sampling. In such cases, patients may choose hysterectomy to address these bothersome symptoms, but the indication is the symptoms, not EH.</p><p></p><p class="headingAnchor" id="H1338276487"><span class="h3">Endometrial surveillance</span></p><p class="headingAnchor" id="H3011699459"><span class="h4">EH without atypia: Premenopausal patients</span><span class="headingEndMark"> — </span>For premenopausal patients with a diagnosis of EH without atypia initially managed with observation or progestin therapy, we repeat endometrial biopsy every three to six months for one year  (<a class="graphic graphic_algorithm graphicRef131599" href="/d/graphic/131599.html" rel="external">algorithm 1</a>). If endometrial carcinoma is found at any point, hysterectomy is standard therapy; however, select patients are candidates for fertility preservation. (See  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma"</a>.)</p><p>If biopsy results show:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal endometrium</strong> and:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient desires pregnancy (and there are no medical contraindications), the patient can try to conceive. (See <a class="local">'Fertility and pregnancy after treatment'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the menstrual pattern normalizes  (<a class="graphic graphic_table graphicRef103238" href="/d/graphic/103238.html" rel="external">table 6</a>), repeat endometrial biopsy is not required. With a normal menstrual pattern, it is highly likely that the desired outcome of a balanced endometrium has been achieved.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the bleeding pattern does not normalize, progestin therapy or combined estrogen and progestin contraceptives (COCs) is prescribed indefinitely. (See <a class="local">'Maintenance therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent EH without atypia</strong>, we perform a dilation and curettage (D&amp;C) and hysteroscopy to exclude more severe EH or endometrial carcinoma  (<a class="graphic graphic_algorithm graphicRef131602" href="/d/graphic/131602.html" rel="external">algorithm 5</a>). Focal lesions may be missed with office endometrial biopsy, and hysteroscopy allows inspection of the entire uterine cavity. If endometrial curettage results show:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal endometrium</strong>, we continue progestin therapy and repeat the endometrial biopsy in three to six months (see <a class="local">'Maintenance therapy'</a> below). If the biopsy shows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Normal endometrium, we treat based on desire for pregnancy and menstrual pattern, as detailed above.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Persistent EH without atypia, options include one, or a combination, of the following: request a second pathology review, continue progestin therapy and repeat endometrial biopsy in three to six months, reduce modifiable risk factors and repeat endometrial biopsy in three to six months  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 2</a>), consult a gynecologic oncologist.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>EH with atypia, we follow the algorithm for premenopausal patients with a diagnosis of EH with atypia  (<a class="graphic graphic_algorithm graphicRef131597" href="/d/graphic/131597.html" rel="external">algorithm 4</a>), which is detailed below. (See <a class="local">'EH with atypia: Premenopausal patients'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent EH without atypia</strong>, we increase the progestin dose (see <a class="local">'Maintenance therapy'</a> below) and repeat the endometrial biopsy in three to six months. If the biopsy shows normal endometrium, we treat based on desire for pregnancy and menstrual pattern, as detailed above.</p><p></p><p class="bulletIndent2">If any EH is found, we discuss the option of definitive surgical management with hysterectomy. Progestin therapy may be continued in select patients who are strongly motivated to preserve fertility, and in those patients willing to accept the risk of early or advanced endometrial carcinoma. Referral to a gynecologic oncologist is also appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EH with atypia</strong>, we follow the algorithm for premenopausal patients with a diagnosis of EH with atypia  (<a class="graphic graphic_algorithm graphicRef131597" href="/d/graphic/131597.html" rel="external">algorithm 4</a>), which is detailed below. (See <a class="local">'EH with atypia: Premenopausal patients'</a> below.)</p><p></p><p class="headingAnchor" id="H4102735845"><span class="h4">EH without atypia: Postmenopausal patients</span><span class="headingEndMark"> — </span>For postmenopausal patients with a diagnosis of EH without atypia who are treated with progestins, we repeat the endometrial biopsy every three to six months for up to one year  (<a class="graphic graphic_algorithm graphicRef131603" href="/d/graphic/131603.html" rel="external">algorithm 2</a>).</p><p>If biopsy results show:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal endometrium</strong> and:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient has no further bleeding, the need for maintenance therapy is based on the presence or absence of risk factors (see <a class="local">'Goal of management'</a> above). If no risk factors are present, expectant management is reasonable. Endometrial biopsy is advised if abnormal uterine bleeding recurs.</p><p></p><p class="bulletIndent2">If risk factors are present, progestin therapy (including combined estrogen-progestin contraceptives [COC]) is prescribed indefinitely. (See <a class="local">'Maintenance therapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient continues to have postmenopausal bleeding, we perform D&amp;C with hysteroscopy to exclude focal pathology. If the biopsy shows normal endometrium, maintenance progestin therapy is initiated and repeat endometrial biopsy is performed every three to six months for up to one year. (See <a class="local">'Maintenance therapy'</a> below.)</p><p></p><p class="bulletIndent2">If any EH (with or without atypia) recurs, hysterectomy is performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent EH without atypia</strong>, we perform D&amp;C with hysteroscopy to exclude more severe EH or endometrial carcinoma.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If EH without atypia is found, a consultation with a gynecologic oncologist and/or a second pathology review to confirm the classification is often warranted. The patient may be treated with hysterectomy or a higher total progestin dose (see <a class="local">'Maintenance therapy'</a> below). If progestin therapy is chosen, repeat endometrial biopsy is performed every three to six months for up to one to two years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EH with atypia or endometrial carcinoma</strong>, hysterectomy is performed.</p><p></p><p class="headingAnchor" id="H2565287564"><span class="h4">EH with atypia: Premenopausal patients</span><span class="headingEndMark"> — </span>For premenopausal patients with a diagnosis of EH with atypia initially managed with progestin therapy, we repeat endometrial biopsy every three to six months for up to two years  (<a class="graphic graphic_algorithm graphicRef131597" href="/d/graphic/131597.html" rel="external">algorithm 4</a>). If endometrial carcinoma is found at any point, hysterectomy is standard therapy; however, select patients are candidates for fertility preservation. (See  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma"</a>.)</p><p>If biopsy results show:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal endometrium</strong> – It is reasonable to perform an additional one to two biopsies to confirm the absence of EH or concomitant carcinoma [<a href="#rid86">86</a>]. If normal endometrium is confirmed and the patient desires pregnancy (and there are no medical contraindications), the patient can try to conceive (see <a class="local">'Fertility and pregnancy after treatment'</a> below). If the patient does not desire pregnancy, maintenance progestin therapy is continued. (See <a class="local">'Maintenance therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EH without atypia</strong> – We follow the algorithm for premenopausal patients with a diagnosis of EH without atypia  (<a class="graphic graphic_algorithm graphicRef131599" href="/d/graphic/131599.html" rel="external">algorithm 1</a>), which is detailed above. (See <a class="local">'EH without atypia: Premenopausal patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent EH</strong> <strong>with atypia</strong> – We perform D&amp;C with hysteroscopy to exclude endometrial carcinoma  (<a class="graphic graphic_algorithm graphicRef131598" href="/d/graphic/131598.html" rel="external">algorithm 6</a>). If the biopsy shows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal endometrium, we treat based on desire for pregnancy and menstrual pattern, as detailed above.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>EH without atypia, we continue progestin therapy at the same dose (see <a class="local">'Maintenance therapy'</a> below) and repeat endometrial biopsy is performed in three months. Further follow-up of these patients is detailed in the algorithm  (<a class="graphic graphic_algorithm graphicRef131598" href="/d/graphic/131598.html" rel="external">algorithm 6</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent EH with atypia, we recommend a second pathology review and a consultation with a gynecologic oncologist to discuss management options.</p><p></p><p class="headingAnchor" id="H1791702173"><span class="h4">EH with atypia: Postmenopausal patients</span><span class="headingEndMark"> — </span>Most postmenopausal patients with a diagnosis of EH with atypia are treated with hysterectomy (see <a class="local">'Preferred treatment: Hysterectomy'</a> above); however, for those patients in whom progestin is prescribed, we perform endometrial sampling every three to six months for two years  (<a class="graphic graphic_algorithm graphicRef131604" href="/d/graphic/131604.html" rel="external">algorithm 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>If endometrial sampling shows EH, hysteroscopy and D&amp;C should be performed, and stronger consideration is given to hysterectomy. If the patient cannot undergo surgical management, subsequent evaluations should be tailored to the individual patient's current and future risk for endometrial carcinoma, the presence or absence of abnormal uterine bleeding, and/or the severity of medical comorbidities precluding surgical management [<a href="#rid87">87</a>]. Referral to a gynecologic oncologist is appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If complete regression of EH is achieved over one to two years and the patient has no bleeding, transvaginal ultrasound may be performed annually. Maintenance progestin therapy is often appropriate and may be continued indefinitely in patients with risk factors for endometrial carcinoma (eg, chronic ovulatory dysfunction, obesity, early menarche, late menopause, increasing age, <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> therapy, Lynch syndrome, Cowden syndrome  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 2</a>)) or in patients with recurrent postmenopausal bleeding [<a href="#rid88">88</a>]. This is discussed in detail below (see <a class="local">'Postmenopausal patients'</a> below). If transvaginal ultrasound is abnormal (eg, &gt;4 mm endometrial thickness), D&amp;C with or without hysteroscopy should be performed.</p><p></p><p class="headingAnchor" id="H2121027911"><span class="h1">MAINTENANCE THERAPY</span><span class="headingEndMark"> — </span>Following initial progestin treatment, maintenance therapy is often appropriate and may be continued indefinitely in patients with ongoing risk factors for endometrial carcinoma (eg, chronic ovulatory dysfunction, obesity, early menarche, late menopause, increasing age, <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> therapy, Lynch syndrome, Cowden syndrome  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 2</a>)) or persistent postmenopausal bleeding.</p><p>In our practice, we prefer the use of the <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG)-releasing intrauterine device (IUD [LNG 52 mg]) rather than oral progestins for maintenance therapy in both premenopausal and postmenopausal patients.</p><p class="headingAnchor" id="H3758622090"><span class="h2">Premenopausal patients</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with chronic ovulatory dysfunction that cannot be corrected (eg, polycystic ovary syndrome), a combined estrogen and progestin oral contraceptive (COC) is a good option in those who do not desire pregnancy and prefer not to use an IUD. Progestin therapy may be continued as long as chronic anovulation is present and there are risk factors for the development of EH. (See  <a class="medical medical_review" href="/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults", section on 'Menstrual dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those who cannot or prefer not to take a progestin-containing contraceptive, alternative options for endometrial protection include cyclic or continuous progestins not approved for contraception  (<a class="graphic graphic_table graphicRef115020" href="/d/graphic/115020.html" rel="external">table 3</a>).</p><p></p><p class="headingAnchor" id="H3752981073"><span class="h2">Postmenopausal patients</span></p><p class="bulletIndent1"><span class="glyph">●</span>In the absence of hot flashes, we treat with progestin only and prefer the LNG 52 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with hot flashes, we offer a trial of progestin-only medication. Oral progestins may reduce hot flashes and have not been associated with increased breast cancer risk, although safety data are limited [<a href="#rid89">89-92</a>]. We also encourage behavioral modification (eg, dressing in layers of clothing that can be easily shed, avoiding triggers [such as spicy foods and stressful situations]) to reduce the number of hot flashes. (See  <a class="medical medical_review" href="/d/html/7390.html" rel="external">"Menopausal hot flashes", section on 'Women with mild hot flashes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with bothersome hot flashes that do not respond to the above measures and who are candidates for postmenopausal estrogen therapy: For EH at high risk of progression, we use the LNG 52 mg combined with low-dose postmenopausal estrogen, and for low-risk EH, we use a continuous estrogen-progestin regimen. Breast cancer risk with hormonal medication and nonhormonal pharmacotherapy for the treatment of hot flashes are discussed separately. (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks", section on 'Breast cancer'</a> and  <a class="medical medical_review" href="/d/html/7390.html" rel="external">"Menopausal hot flashes", section on 'Nonhormonal pharmacotherapy'</a>.)</p><p></p><p class="headingAnchor" id="H4196702871"><span class="h2">Management of persistence or progression on maintenance therapy</span><span class="headingEndMark"> — </span>An increase in maintenance therapy is needed when there is progression or persistence of EH. Options include:</p><p class="bulletIndent1"><span class="glyph">●</span>If the patient has the LNG 52 mg, add an oral progestin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient is on an oral progestin, the LNG 52 mg can be added, the oral dose increased, or a more potent progestin can be used. (See <a class="local">'Progestin therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H423928863"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H1555126902"><span class="h2">Patients on tamoxifen</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">Tamoxifen</a>, a nonsteroidal selective estrogen receptor modulator (SERM), may be used as adjuvant treatment for patients with estrogen receptor-positive breast cancer or chemoprevention in those at increased risk for breast cancer. However, its use is associated with an increased risk of uterine pathology. The risk of endometrial hyperplasia, as well as management of endometrial hyperplasia in such patients, is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/14204.html" rel="external">"Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy"</a>.)</p><p class="headingAnchor" id="H3812339805"><span class="h2">Proliferative endometrium</span><span class="headingEndMark"> — </span>Proliferative endometrium is not a form of EH but suggests active estradiol secretion, akin to that seen in the proliferative phase of the menstrual cycle. However, proliferative patterns observed in anovulatory premenopausal patients or in postmenopausal patients, if not corrected, signify an excess of estrogen that may place them at higher risk of developing EH [<a href="#rid93">93,94</a>]. In one retrospective series including over 1800 postmenopausal patients (age ≥55 years) undergoing endometrial biopsy, patients with proliferative endometrium (16 percent) compared with atrophic endometrium had a fourfold increased risk of developing EH (6.2 versus 1.2 percent) or endometrial carcinoma (5.8 versus 1.8 percent) [<a href="#rid95">95</a>]. Of the patients who developed EH or endometrial carcinoma, more than one-half did so five or more years after their initial diagnosis of proliferative endometrium. (See  <a class="medical medical_review" href="/d/html/3217.html" rel="external">"Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis"</a>.)</p><p>Treatment of proliferative endometrium should be solely based on the nature of the patient's symptoms that prompted the biopsy and the effect of such symptoms on quality of life. In our practice, we favor the <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG)-releasing intrauterine device (IUD [LNG 52 mg; Mirena, Liletta]) for premenopausal patients. For postmenopausal patients, consideration can be given to either the LNG 52 mg or oral progestins; however, the LNG 52 is favored in postmenopausal patients with a history of EH. </p><p>The frequency and duration of follow-up for such patients is uncertain. For postmenopausal patients, some experts perform endometrial sampling every three to six months for one year [<a href="#rid96">96</a>]; this is consistent with our practice. For premenopausal patients, additional sampling is typically not indicated if their bleeding patterns return to baseline. For premenopausal patients in whom their bleeding does not return to baseline, or with risk factors for endometrial cancer  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 2</a>), we perform endometrial sampling every three to six months for one year.</p><p class="headingAnchor" id="H630830913"><span class="h2">Fertility and pregnancy after treatment</span><span class="headingEndMark"> — </span>Many premenopausal patients who choose progestin therapy for treatment of EH may successfully conceive a pregnancy after regression. In two meta-analyses, both evaluating reproductive outcomes following fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma, 30 to 34 percent of patients achieved one or more pregnancies after treatment [<a href="#rid97">97,98</a>]; the live birth rate was between 14 and 35 percent in one study [<a href="#rid98">98</a>].</p><p>Patients who choose to try to conceive after regression of EH should stop progestin therapy as some of these medications may prevent ovulation and are not recommended during pregnancy. If the patient does not become pregnant within a year, we repeat an endometrial biopsy annually or more frequently if menses are irregular [<a href="#rid99">99</a>]; consultation with a reproductive endocrinology and infertility specialist is also appropriate.</p><p>Following pregnancy, maintenance progestin therapy and/or surveillance with endometrial biopsy is <strong>not</strong> required if the patient has regular cycles. If regular cycles do not resume, we perform a repeat endometrial biopsy. If contraception is desired, we recommend the LNG 52 mg or continuous combined oral contraceptives (COCs).</p><p>Hysterectomy is not recommended after birth in the absence of recurrent EH for most patients. In the case of recurrent EH with atypia in patients who desire further fertility, retreatment with progestins has been utilized [<a href="#rid100">100</a>]. However, a patient's risk factors for EH should be readdressed, and hysterectomy should be considered after the patient has completed childbearing. Patients with a hereditary endometrial cancer syndrome (eg, Lynch syndrome, Cowden syndrome) may be managed differently. (See  <a class="medical medical_review" href="/d/html/101430.html" rel="external">"Fertility preservation in patients with endometrial carcinoma"</a> and  <a class="medical medical_review" href="/d/html/3224.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer", section on 'Risk-reducing hysterectomy with delayed or no BSO'</a>.)</p><p class="headingAnchor" id="H525446510"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121144.html" rel="external">"Society guideline links: Uterine cancer"</a>.)</p><p class="headingAnchor" id="H1393704771"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of treatment</strong> – Endometrial hyperplasia (EH) is categorized into two groups: EH without atypia and EH with atypia (also referred to as endometrial intraepithelial neoplasia [EIN]). EH may progress to, or coexist with, endometrial carcinoma. The choice of treatment (observation, progestin therapy, or hysterectomy) is based on several factors: type of EH (with or without atypia), menopausal status, desire for fertility, contraceptive needs, and risk factors present  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 2</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Goal of management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EH without atypia</strong> – Untreated EH without atypia has a risk of progression to malignancy of approximately 10 percent or less over 20 years. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with EH without atypia, we suggest progestin therapy with endometrial sampling rather than hysterectomy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef131599" href="/d/graphic/131599.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef131603" href="/d/graphic/131603.html" rel="external">algorithm 2</a>). Treatment with progestin therapy reduces the risk of progression to endometrial carcinoma to approximately 2 percent at 10 years. Observation is a reasonable alternative for premenopausal patients who have no risk factors for endometrial carcinoma  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 2</a>) and/or who have contraindications to progestins. For postmenopausal patients with endometrial carcinoma risk factors and/or contraindications to progestins, we discuss surgical management with hysterectomy for definitive management. (See <a class="local">'Alternate for patients at low risk of progression: Observation'</a> above and <a class="local">'Preferred: Medical or surgical treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EH with atypia</strong> – Untreated EH with atypia has a risk of progression to endometrial carcinoma of up to 40 percent over 20 years, and coexistent endometrial carcinoma may be present in up to 40 percent of these patients. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with EH with atypia who are postmenopausal or who are premenopausal and have completed childbearing, we recommend hysterectomy rather than progestin therapy with endometrial sampling (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>)  (<a class="graphic graphic_algorithm graphicRef131597" href="/d/graphic/131597.html" rel="external">algorithm 4</a> and <a class="graphic graphic_algorithm graphicRef131604" href="/d/graphic/131604.html" rel="external">algorithm 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For premenopausal patients with EH with atypia who wish to preserve fertility, we suggest progestin therapy with endometrial sampling rather than hysterectomy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>)  (<a class="graphic graphic_algorithm graphicRef131597" href="/d/graphic/131597.html" rel="external">algorithm 4</a>). (See <a class="local">'Preferred treatment: Hysterectomy'</a> above and <a class="local">'Alternate treatment: Progestin therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients undergoing hysterectomy as treatment for EH with atypia, we suggest hysterectomy without bilateral oophorectomy rather than with bilateral oophorectomy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Role of oophorectomy and salpingectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progestin therapy</strong> – Common progestin treatments for EH (any type) include the <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG)-releasing intrauterine device (IUD [LNG 52 mg; Mirena, Liletta]), oral <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a>, or oral <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (MPA  (<a class="graphic graphic_table graphicRef115020" href="/d/graphic/115020.html" rel="external">table 3</a>)). Combined oral estrogen-progestin contraceptives (COCs) have not been well studied for EH treatment but are an option for some premenopausal patients. (See <a class="local">'Progestin therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with EH (with or without atypia) undergoing medical management, we suggest the LNG 52 mg rather than systemic progestins (oral, intramural, subcutaneous, or transdermal (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>)). Studies have demonstrated that the LNG 52 mg compared with oral progestins for the treatment of EH is associated with higher regression rates and lower relapse rates. (See <a class="local">'Evidence of the efficacy of progestin therapy'</a> above and <a class="local">'Evidence of the efficacy of progestin therapy'</a> above and <a class="local">'Choice of progestin'</a> above.)</p><p></p><p class="headingAnchor" id="H1891453639"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert Giuntoli, II, MD, and Howard Zacur, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Emons G, Beckmann MW, Schmidt D, et al. New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd 2015; 75:135.</a></li><li><a class="nounderline abstract_t">Zhao J, Hu Y, Zhao Y, et al. Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments. BMC Womens Health 2021; 21:312.</a></li><li><a class="nounderline abstract_t">Yin J, Ma S, Shan Y, et al. Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments. Cancer Prev Res (Phila) 2020; 13:403.</a></li><li><a class="nounderline abstract_t">Pal N, Broaddus RR, Urbauer DL, et al. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol 2018; 131:109.</a></li><li><a class="nounderline abstract_t">Zhou S, Xu Z, Yang B, et al. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment. J Gynecol Oncol 2021; 32:e57.</a></li><li><a class="nounderline abstract_t">Terakawa N, Kigawa J, Taketani Y, et al. The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. J Obstet Gynaecol Res 1997; 23:223.</a></li><li><a class="nounderline abstract_t">Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985; 56:403.</a></li><li><a class="nounderline abstract_t">Reed SD, Newton KM, Garcia RL, et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol 2010; 116:365.</a></li><li><a class="nounderline abstract_t">Lacey JV Jr, Sherman ME, Rush BB, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010; 28:788.</a></li><li><a class="nounderline abstract_t">Lacey JV Jr, Ioffe OB, Ronnett BM, et al. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. Br J Cancer 2008; 98:45.</a></li><li><a class="nounderline abstract_t">Gallos ID, Shehmar M, Thangaratinam S, et al. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203:547.e1.</a></li><li><a class="nounderline abstract_t">Bian J, Shao H, Liu H, et al. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia. Reprod Sci 2015; 22:758.</a></li><li><a class="nounderline abstract_t">Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol 2015; 213:469.</a></li><li><a class="nounderline abstract_t">Reed SD, Voigt LF, Newton KM, et al. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol 2009; 113:655.</a></li><li><a class="nounderline abstract_t">Gal D, Edman CD, Vellios F, Forney JP. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol 1983; 146:316.</a></li><li><a class="nounderline abstract_t">Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003; 188:1297.</a></li><li><a class="nounderline abstract_t">Gallos ID, Krishan P, Shehmar M, et al. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Hum Reprod 2013; 28:1231.</a></li><li><a class="nounderline abstract_t">Vereide AB, Arnes M, Straume B, et al. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003; 91:526.</a></li><li><a class="nounderline abstract_t">Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106:812.</a></li><li><a class="nounderline abstract_t">Travaglino A, Raffone A, Saccone G, et al. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology 2019; 74:676.</a></li><li><a class="nounderline abstract_t">Vetter MH, Smith B, Benedict J, et al. Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. Am J Obstet Gynecol 2020; 222:60.e1.</a></li><li><a class="nounderline abstract_t">Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study. Am J Obstet Gynecol 1995; 172:1488.</a></li><li><a class="nounderline abstract_t">Matsuo K, Ramzan AA, Gualtieri MR, et al. Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. Gynecol Oncol 2015; 139:261.</a></li><li><a class="nounderline abstract_t">Jernigan AM, Maurer KA, Cooper K, et al. Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists: a prospective cohort study. Am J Obstet Gynecol 2015; 213:350.e1.</a></li><li><a class="nounderline abstract_t">Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. Obstet Gynecol 2012; 120:1160.</a></li><li><a class="nounderline abstract_t">Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207:266.e1.</a></li><li><a class="nounderline abstract_t">Orbo A, Vereide A, Arnes M, et al. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 2014; 121:477.</a></li><li><a class="nounderline abstract_t">Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 2012; 125:263.</a></li><li><a class="nounderline abstract_t">Gallos ID, Krishan P, Shehmar M, et al. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod 2013; 28:2966.</a></li><li><a class="nounderline abstract_t">Mandelbaum RS, Ciccone MA, Nusbaum DJ, et al. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. Am J Obstet Gynecol 2020; 223:103.e1.</a></li><li><a class="nounderline abstract_t">Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125:477.</a></li><li><a class="nounderline abstract_t">Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90:434.</a></li><li><a class="nounderline abstract_t">Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007; 31:988.</a></li><li><a class="nounderline abstract_t">Perino A, Quartararo P, Catinella E, et al. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil 1987; 18:137.</a></li><li><a class="nounderline abstract_t">Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002; 186:651.</a></li><li><a class="nounderline abstract_t">Suzuki Y, Chen L, Hou JY, et al. Systemic Progestins and Progestin-Releasing Intrauterine Device Therapy for Premenopausal Patients With Endometrial Intraepithelial Neoplasia. Obstet Gynecol 2023; 141:979.</a></li><li><a class="nounderline abstract_t">Casper RF. Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil Menopausal Stud 1996; 41:16.</a></li><li><a class="nounderline abstract_t">Cockrum RH, Soo J, Ham SA, et al. Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age. Obstet Gynecol 2022; 140:477.</a></li><li><a class="nounderline abstract_t">Dolapcioglu K, Boz A, Baloglu A. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study. Clin Exp Obstet Gynecol 2013; 40:122.</a></li><li><a class="nounderline abstract_t">Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005; 97:924.</a></li><li><a class="nounderline abstract_t">Wildemeersch D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007; 57:210.</a></li><li><a class="nounderline abstract_t">Westin SN, Fellman B, Sun CC, et al. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol 2021; 224:191.e1.</a></li><li><a class="nounderline abstract_t">Wang Y, Nisenblat V, Tao L, et al. Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience. J Gynecol Oncol 2019; 30:e49.</a></li><li><a class="nounderline abstract_t">Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia: ACOG Clinical Consensus No. 5. Obstet Gynecol 2023; 142:735.</a></li><li><a class="nounderline abstract_t">Simpson AN, Feigenberg T, Clarke BA, et al. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecol Oncol 2014; 133:229.</a></li><li><a class="nounderline abstract_t">Cholakian D, Hacker K, Fader AN, et al. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer. Gynecol Oncol 2016; 140:234.</a></li><li><a class="nounderline abstract_t">Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989; 160:126.</a></li><li><a class="nounderline abstract_t">Horn LC, Schnurrbusch U, Bilek K, et al. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 2004; 14:348.</a></li><li class="breakAll">Gallos ID, Alazzam M, Clark TJ, et al. Management of Endometrial Hyperplasia. Green-top Guideline No. 67. https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf (Accessed on July 30, 2015).</li><li><a class="nounderline abstract_t">Nooh AM, Abdeldayem HM, Girbash EF, et al. Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia. Reprod Sci 2016; 23:448.</a></li><li><a class="nounderline abstract_t">Marra C, Penati C, Ferrari L, et al. Treatment of simple and complex endometrial non-atypical hyperplasia with natural progesterone: response rate to different doses. Gynecol Endocrinol 2014; 30:899.</a></li><li><a class="nounderline abstract_t">Kurman RJ, Félix JC, Archer DF, et al. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000; 96:373.</a></li><li><a class="nounderline abstract_t">ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001; 16:1527.</a></li><li><a class="nounderline abstract_t">Epplein M, Reed SD, Voigt LF, et al. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol 2008; 168:563.</a></li><li><a class="nounderline abstract_t">Lindahl B, Willén R. Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients. Anticancer Res 1991; 11:403.</a></li><li><a class="nounderline abstract_t">Affinito P, Di Carlo C, Di Mauro P, et al. Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone. Maturitas 1994; 20:191.</a></li><li><a class="nounderline abstract_t">Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril 1998; 69:96.</a></li><li><a class="nounderline abstract_t">Allison KH, Reed SD, Voigt LF, et al. Diagnosing endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol 2008; 32:691.</a></li><li><a class="nounderline abstract_t">Rakha E, Wong SC, Soomro I, et al. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. Am J Surg Pathol 2012; 36:1683.</a></li><li><a class="nounderline abstract_t">Attard Montalto S, Coutts M, Devaja O, et al. Accuracy of frozen section diagnosis at surgery in pre- malignant and malignant lesions of the endometrium. Eur J Gynaecol Oncol 2008; 29:435.</a></li><li><a class="nounderline abstract_t">Salman MC, Usubutun A, Dogan NU, Yuce K. The accuracy of frozen section analysis at hysterectomy in patients with atypical endometrial hyperplasia. Clin Exp Obstet Gynecol 2009; 36:31.</a></li><li><a class="nounderline abstract_t">Morotti M, Menada MV, Moioli M, et al. Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Gynecol Oncol 2012; 125:536.</a></li><li><a class="nounderline abstract_t">Indermaur MD, Shoup B, Tebes S, Lancaster JM. The accuracy of frozen pathology at time of hysterectomy in patients with complex atypical hyperplasia on preoperative biopsy. Am J Obstet Gynecol 2007; 196:e40.</a></li><li><a class="nounderline abstract_t">Matsuo K, Violette CJ, Tavakoli A, et al. Increasing Utilization of Surgical Nodal Evaluation at Hysterectomy for Endometrial Hyperplasia. Obstet Gynecol 2022; 139:1152.</a></li><li><a class="nounderline abstract_t">Dioun S, Chen L, Melamed A, et al. Uptake and Outcomes of Sentinel Lymph Node Mapping in Women With Atypical Endometrial Hyperplasia. Obstet Gynecol 2021; 137:924.</a></li><li><a class="nounderline abstract_t">Takeshima N, Hirai Y, Yano K, et al. Ovarian metastasis in endometrial carcinoma. Gynecol Oncol 1998; 70:183.</a></li><li><a class="nounderline abstract_t">Boronow RC, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 1984; 63:825.</a></li><li><a class="nounderline abstract_t">Lee TS, Kim JW, Kim TJ, et al. Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nation-wide study conducted by the Korean Gynecologic Oncology Group. Gynecol Oncol 2009; 115:26.</a></li><li><a class="nounderline abstract_t">Matsuo K, Cahoon SS, Yoshihara K, et al. Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer. Obstet Gynecol 2016; 128:127.</a></li><li><a class="nounderline abstract_t">Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60:2035.</a></li><li><a class="nounderline abstract_t">Zhang Q, Qi G, Kanis MJ, et al. Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia. Oncotarget 2017; 8:57642.</a></li><li><a class="nounderline abstract_t">Pronin SM, Novikova OV, Andreeva JY, Novikova EG. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential. Int J Gynecol Cancer 2015; 25:1010.</a></li><li><a class="nounderline abstract_t">Pashov AI, Tskhay VB, Ionouchene SV. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study. Gynecol Endocrinol 2012; 28:559.</a></li><li><a class="nounderline abstract_t">Kistner RW, Lewis JL, Steiner GJ. Effects of clomiphene citrate on endometrial hyperplasia in the premenopausal female. Cancer 1966; 19:115.</a></li><li><a class="nounderline abstract_t">Tas M, Kutuk MS, Serin IS, et al. Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats. Gynecol Endocrinol 2013; 29:311.</a></li><li><a class="nounderline abstract_t">Chae-Kim J, Garg G, Gavrilova-Jordan L, et al. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2021; 31:1499.</a></li><li><a class="nounderline abstract_t">Atiomo W. Is there any move to use metformin for endometrial hyperplasia in routine clinical practice? BJOG 2020; 127:858.</a></li><li><a class="nounderline abstract_t">Cianferoni L, Giannini A, Franchini M. Hysteroscopic resection of endometrial hyperplasia. J Am Assoc Gynecol Laparosc 1999; 6:151.</a></li><li><a class="nounderline abstract_t">Alonso S, Castellanos T, Lapuente F, Chiva L. Hysteroscopic surgery for conservative management in endometrial cancer: a review of the literature. Ecancermedicalscience 2015; 9:505.</a></li><li><a class="nounderline abstract_t">Argenta PA, Kassing M, Truskinovsky AM, Svendsen CA. Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women: a prospective, pilot study. BJOG 2013; 120:795.</a></li><li><a class="nounderline abstract_t">Aubrey C, Black K, Campbell S, Pin S. Endometrial cancer and bariatric surgery: A scoping review. Surg Obes Relat Dis 2019; 15:497.</a></li><li><a class="nounderline abstract_t">McCawley GM, Ferriss JS, Geffel D, et al. Cancer in obese women: potential protective impact of bariatric surgery. J Am Coll Surg 2009; 208:1093.</a></li><li><a class="nounderline abstract_t">Lindahl B, Willén R. Steroid receptor concentrations as a prognostic factor in atypical endometrial hyperplasia. Anticancer Res 1998; 18:3793.</a></li><li><a class="nounderline abstract_t">Gunderson CC, Dutta S, Fader AN, et al. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecol Oncol 2014; 132:33.</a></li><li><a class="nounderline abstract_t">Gallos ID, Devey J, Ganesan R, Gupta JK. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study. Gynecol Oncol 2013; 130:58.</a></li><li><a class="nounderline abstract_t">Ørbo A, Arnes M, Vereide AB, Straume B. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG 2016; 123:1512.</a></li><li><a class="nounderline abstract_t">Gull B, Karlsson B, Milsom I, Granberg S. Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer. Am J Obstet Gynecol 2003; 188:401.</a></li><li><a class="nounderline abstract_t">Sletten ET, Arnes M, Lysa LM, et al. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study. Anticancer Res 2017; 37:2529.</a></li><li><a class="nounderline abstract_t">Irani J, Salomon L, Oba R, et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11:147.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Barton DL, Sloan JA, et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause 2008; 15:655.</a></li><li><a class="nounderline abstract_t">Barton D, Loprinzi C, Quella S, et al. Depomedroxyprogesterone acetate for hot flashes. J Pain Symptom Manage 2002; 24:603.</a></li><li><a class="nounderline abstract_t">Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 2012; 19:886.</a></li><li><a class="nounderline abstract_t">Jetley S, Rana S, Jairajpuri ZS. Morphological spectrum of endometrial pathology in middle-aged women with atypical uterine bleeding: A study of 219 cases. J Midlife Health 2013; 4:216.</a></li><li><a class="nounderline abstract_t">Damle RP, Dravid NV, Suryawanshi KH, et al. Clinicopathological Spectrum of Endometrial Changes in Peri-menopausal and Post-menopausal Abnormal Uterine Bleeding: A 2 Years Study. J Clin Diagn Res 2013; 7:2774.</a></li><li><a class="nounderline abstract_t">Rotenberg O, Doulaveris G, Fridman D, et al. Long-term outcome of postmenopausal women with proliferative endometrium on endometrial sampling. Am J Obstet Gynecol 2020; 223:896.e1.</a></li><li><a class="nounderline abstract_t">Abraham C. Proliferative Endometrium in Menopause: To Treat or Not to Treat? Obstet Gynecol 2023; 141:265.</a></li><li><a class="nounderline abstract_t">Koskas M, Uzan J, Luton D, et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 2014; 101:785.</a></li><li><a class="nounderline abstract_t">Wei J, Zhang W, Feng L, Gao W. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review. Medicine (Baltimore) 2017; 96:e8034.</a></li><li><a class="nounderline abstract_t">Park JY, Kim DY, Kim TJ, et al. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol 2013; 122:7.</a></li><li><a class="nounderline abstract_t">Park JY, Lee SH, Seong SJ, et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 2013; 129:7.</a></li></ol></div><div id="topicVersionRevision">Topic 16723 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25797956" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : New WHO Classification of Endometrial Hyperplasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34433451" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32015095" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29215513" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34085795" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9255033" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4005805" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664397" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20065186" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18026193" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20934679" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25536958" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25797236" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300331" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Progestin therapy of complex endometrial hyperplasia with and without atypia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859142" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748501" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23466671" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675671" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16400639" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30347477" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31401259" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7755059" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26238457" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25981846" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23090535" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Management of endometrial precancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021687" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24286192" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22196499" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23975691" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31978437" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22245711" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9277658" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592264" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3115027" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11967486" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intrauterine progesterone treatment of early endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37023446" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systemic Progestins and Progestin-Releasing Intrauterine Device Therapy for Premenopausal Patients With Endometrial Intraepithelial Neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8673152" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Regulation of estrogen/progestogen receptors in the endometrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35926206" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23724525" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15943993" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17270370" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32805208" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30887764" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37590985" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia: ACOG Clinical Consensus No. 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24561246" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26706662" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2912075" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086736" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086736" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26718306" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25111756" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Treatment of simple and complex endometrial non-atypical hyperplasia with natural progesterone: response rate to different doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10960628" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Norethindrone acetate and estradiol-induced endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11425842" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ovarian and endometrial function during hormonal contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682485" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1826823" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7715472" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9457941" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Experience with a novel vaginal progesterone preparation in a donor oocyte program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347507" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diagnosing endometrial hyperplasia: why is it so difficult to agree?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23073327" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19051807" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Accuracy of frozen section diagnosis at surgery in pre- malignant and malignant lesions of the endometrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400415" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The accuracy of frozen section analysis at hysterectomy in patients with atypical endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22361087" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17466676" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The accuracy of frozen pathology at time of hysterectomy in patients with complex atypical hyperplasia on preoperative biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35675614" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Increasing Utilization of Surgical Nodal Evaluation at Hysterectomy for Endometrial Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33831939" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Uptake and Outcomes of Sentinel Lymph Node Mapping in Women With Atypical Endometrial Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740687" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Ovarian metastasis in endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6728365" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19635630" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nation-wide study conducted by the Korean Gynecologic Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27275802" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3652025" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28915701" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25950126" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22296608" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5948088" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Effects of clomiphene citrate on endometrial hyperplasia in the premenopausal female.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23305503" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34785524" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32096892" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Is there any move to use metformin for endometrial hyperplasia in routine clinical practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10226123" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hysteroscopic resection of endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25729418" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hysteroscopic surgery for conservative management in endometrial cancer: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23231632" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women: a prospective, pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30700395" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Endometrial cancer and bariatric surgery: A scoping review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19476897" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Cancer in obese women: potential protective impact of bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854498" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Steroid receptor concentrations as a prognostic factor in atypical endometrial hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24316307" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23603367" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630538" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592247" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28476823" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19963436" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18427355" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12551811" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Depomedroxyprogesterone acetate for hot flashes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22453200" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24381462" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Morphological spectrum of endometrial pathology in middle-aged women with atypical uterine bleeding: A study of 219 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24551634" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Clinicopathological Spectrum of Endometrial Changes in Peri-menopausal and Post-menopausal Abnormal Uterine Bleeding: A 2 Years Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32640199" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Long-term outcome of postmenopausal women with proliferative endometrium on endometrial sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36649316" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Proliferative Endometrium in Menopause: To Treat or Not to Treat?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388202" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28906392" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23743459" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Hormonal therapy for women with stage IA endometrial cancer of all grades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23283299" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
